An executive order has been signed to accelerate research into psychedelic drug therapies, with the goal of potentially using them for mental health treatment. The order appears to loosen restrictions on psychedelic drug therapy and may fast-track the review of certain substances, including psilocybin. The move has sparked a range of reactions, from cautious optimism to a surge in drugmakers' stock prices.